Importance Although non–vitamin K antagonist oral anticoagulants (NOACs) are
increasingly used to prevent thromboembolic disease, there are limited data on NOAC …

Importance Intracerebral hemorrhage (ICH) is the most devastating adverse event in
patients receiving oral anticoagulation. There is only sparse evidence regarding ICH related …

Objective: To compare the neuroimaging profile and clinical outcomes among patients with
intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral …

Importance Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …

Objective Whether intracerebral hemorrhage (ICH) associated with non–vitamin K
antagonist oral anticoagulants (NOAC‐ICH) has a better outcome compared to ICH …

Intracerebral hemorrhage (ICH) is the second most common subtype of stroke and a critical
disease usually leading to severe disability or death. ICH is more common in Asians …

Importance Although the use of factor Xa (FXa) inhibitors has increased substantially over
the past decade, there are limited data on characteristics and outcomes of FXa inhibitor …

Objectives This cross-sectional survey explored the characteristics and outcomes of direct
oral anticoagulant (DOAC)–associated nontraumatic intracerebral hemorrhages (ICHs) by …

The new oral anticoagulants/non-vitamin K antagonists oral anticoagulants (NOACs) have
recently reached the market and less is known about their safety in comparison to their …

Introduction Intracerebral hemorrhage (ICH) is the most feared complication of oral
anticoagulant therapy (OAT). While anticoagulated patients have increased severity of …